沙利度胺及其类似物：纤维化疾病和眼病免疫调节潜力综述
Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy.
作者信息
Liu Ting, Guo Feng, Zhu Xiaomin, He Xiangge, Xie Lin
机构信息
Department of Ophthalmology, Daping Hospital and Research Institute of Surgery, The Third Military Medical University, People's Liberation Army, Chongqing 400042, P.R. China.
出版信息
Exp Ther Med. 2017 Dec;14(6):5251-5257. doi: 10.3892/etm.2017.5209. Epub 2017 Sep 27.
Abstract
The US Food and Drug Administration approved thalidomide and its analogues for the treatment of erythema nodosum leprosum, in spite of the notoriety of reports of severe birth defects in the middle of the last century. As immunomodulatory drugs, thalidomide and its analogues have been used to effectively treat various diseases. In the present review, preclinical data about the effects of thalidomide and its analogues on the immune system are integrated, including the effects of cytokines on transdifferentiation, the anti-inflammatory effect, immune cell function regulation and angiogenesis. The present review also investigates the latest developments of thalidomide as a therapeutic option for the treatment of idiopathic pulmonary fibrosis, skin fibrosis, and ophthalmopathies.
摘要
尽管在上世纪中叶有关于严重出生缺陷的报道臭名昭著，但美国食品药品监督管理局仍批准了沙利度胺及其类似物用于治疗麻风结节性红斑。作为免疫调节药物，沙利度胺及其类似物已被用于有效治疗各种疾病。在本综述中，整合了关于沙利度胺及其类似物对免疫系统影响的临床前数据，包括细胞因子对转分化的影响、抗炎作用、免疫细胞功能调节和血管生成。本综述还研究了沙利度胺作为治疗特发性肺纤维化、皮肤纤维化和眼病的治疗选择的最新进展。
相似文献
1
Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy.沙利度胺及其类似物：纤维化疾病和眼病免疫调节潜力综述
Exp Ther Med. 2017 Dec;14(6):5251-5257. doi: 10.3892/etm.2017.5209. Epub 2017 Sep 27.
2
Revisiting thalidomide: fighting with caution against idiopathic pulmonary fibrosis.重新审视沙利度胺：谨慎对抗特发性肺纤维化
Drugs Today (Barc). 2012 Oct;48(10):661-71. doi: 10.1358/dot.2012.48.10.1855760.
3
Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders.沙利度胺及其类似物：对炎症性和肿瘤性皮肤病进行免疫调节的潜力
J Drugs Dermatol. 2010 Jul;9(7):814-26.
4
The return of thalidomide: can birth defects be prevented?沙利度胺的回归：出生缺陷能否预防？
Drug Saf. 1999 Sep;21(3):161-9. doi: 10.2165/00002018-199921030-00002.
5
Thalidomide for erythema nodosum leprosum and other applications.沙利度胺用于麻风结节性红斑及其他用途。
Pharmacotherapy. 2003 Apr;23(4):481-93. doi: 10.1592/phco.23.4.481.32115.
6
[Current therapeutic indications of thalidomide and lenalidomide].[沙利度胺和来那度胺的当前治疗适应证]
Med Clin (Barc). 2014 Apr 22;142(8):360-4. doi: 10.1016/j.medcli.2013.04.038. Epub 2013 Jul 3.
7
Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro.沙利度胺治疗麻风结节性红斑：沙利度胺类似物在体外抑制麻风杆菌诱导的肿瘤坏死因子α产生。
Biomed Pharmacother. 2002 Feb;56(1):13-9. doi: 10.1016/s0753-3322(01)00147-0.
8
Thalidomide: an emerging drug in oral mucosal lesions.沙利度胺：一种用于口腔黏膜病变的新兴药物。
Clin J Gastroenterol. 2009 Jun;2(3):149-155. doi: 10.1007/s12328-009-0089-5. Epub 2009 Jun 2.
9
Thalidomide: a review of approved and investigational uses.沙利度胺：已批准及正在研究的用途综述。
Clin Ther. 2003 Feb;25(2):342-95. doi: 10.1016/s0149-2918(03)80085-1.
10
Complete resolution of generalized lichen planus after treatment with thalidomide.使用沙利度胺治疗后，泛发性扁平苔藓完全消退。
J Drugs Dermatol. 2005 Jan-Feb;4(1):86-8.
引用本文的文献
1
Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link?慢性淋巴细胞白血病中的肿瘤细胞存活因子与血管生成：二者关联有多紧密？
Cancers (Basel). 2024 Dec 29;17(1):72. doi: 10.3390/cancers17010072.
2
Some Aspects and Convergence of Human and Veterinary Drug Repositioning.人类和兽医药物再定位的一些方面和趋同。
Molecules. 2024 Sep 20;29(18):4475. doi: 10.3390/molecules29184475.
3
Characterization of monoclonal gammopathy of undetermined significance progression to multiple myeloma through meta-analysis of GEO data.通过对基因表达综合数据库（GEO）数据的荟萃分析，对意义未明的单克隆丙种球蛋白病进展为多发性骨髓瘤进行特征分析。
Heliyon. 2023 Jun 28;9(7):e17298. doi: 10.1016/j.heliyon.2023.e17298. eCollection 2023 Jul.
4
Efficacy of Topical Treatments for the Management of Symptomatic Oral Lichen Planus: A Systematic Review.局部治疗口腔扁平苔藓症状管理的疗效：系统评价。
Int J Environ Res Public Health. 2023 Jan 10;20(2):1202. doi: 10.3390/ijerph20021202.
5
Neuroinflammatory Markers: Key Indicators in the Pathology of Neurodegenerative Diseases.神经炎症标志物：神经退行性疾病病理学中的关键指标。
Molecules. 2022 May 17;27(10):3194. doi: 10.3390/molecules27103194.
6
Molecular Mechanisms and Current Treatment Options for Cancer Cachexia.癌症恶病质的分子机制与当前治疗选择
Cancers (Basel). 2022 Apr 23;14(9):2107. doi: 10.3390/cancers14092107.
7
A review of COVID-19: Treatment strategies and CRISPR/Cas9 gene editing technology approaches to the coronavirus disease.新型冠状病毒肺炎综述：冠状病毒病的治疗策略及CRISPR/Cas9基因编辑技术方法
Saudi J Biol Sci. 2022 Feb;29(2):860-871. doi: 10.1016/j.sjbs.2021.10.020. Epub 2021 Oct 13.
8
Thalidomide-Then and Now: Case Report of a Woman With Thalidomide Embryopathy and Review of Current Thalidomide Uses.沙利度胺的过去与现在：一名患沙利度胺胚胎病女性的病例报告及沙利度胺当前用途综述
Cureus. 2021 Aug 10;13(8):e17070. doi: 10.7759/cureus.17070. eCollection 2021 Aug.
9
Drug repurposing of dermatologic medications to treat coronavirus disease 2019: Science or fiction?皮肤科药物治疗 2019 年冠状病毒病的再利用：科学还是虚构？
Clin Dermatol. 2021 May-Jun;39(3):430-445. doi: 10.1016/j.clindermatol.2021.01.020. Epub 2021 Feb 2.
10
Diagnostic and Treatment Strategies for COVID-19.《COVID-19 的诊断与治疗策略》
AAPS PharmSciTech. 2020 Aug 3;21(6):222. doi: 10.1208/s12249-020-01756-3.
本文引用的文献
1
Isotrifoliol inhibits pro-inflammatory mediators by suppression of TLR/NF-κB and TLR/MAPK signaling in LPS-induced RAW264.7 cells.异槲皮苷通过抑制 TLR/NF-κB 和 TLR/MAPK 信号通路抑制 LPS 诱导的 RAW264.7 细胞中促炎介质的产生。
Int Immunopharmacol. 2017 Apr;45:110-119. doi: 10.1016/j.intimp.2017.01.033. Epub 2017 Feb 10.
2
Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease.免疫调节药物来那度胺而非泊马度胺在类风湿性关节炎和炎症性肠病实验模型中的治疗效果。
Exp Mol Med. 2017 Feb 3;49(2):e290. doi: 10.1038/emm.2016.143.
3
Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues.新型四氟代沙利度胺类似物的抗癌特性
Mol Cancer Ther. 2015 Oct;14(10):2228-37. doi: 10.1158/1535-7163.MCT-15-0320. Epub 2015 Aug 12.
4
Thalidomide-induced teratogenesis: history and mechanisms.沙利度胺诱导的致畸作用：历史与机制
Birth Defects Res C Embryo Today. 2015 Jun;105(2):140-56. doi: 10.1002/bdrc.21096. Epub 2015 Jun 4.
5
Immune modulatory effect of thalidomide on T cells.沙利度胺对T细胞的免疫调节作用。
Transplant Proc. 2015 Apr;47(3):787-90. doi: 10.1016/j.transproceed.2014.12.038.
6
Thalidomide in the treatment of immune reconstitution inflammatory syndrome in HIV patients with neurological tuberculosis.沙利度胺治疗合并神经结核的HIV患者免疫重建炎症综合征
AIDS Patient Care STDS. 2014 Nov;28(11):567-9. doi: 10.1089/apc.2014.0083. Epub 2014 Oct 6.
7
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.泊马度胺联合泼尼松治疗骨髓纤维化伴严重贫血患者的II期研究
Leuk Res. 2014 Sep;38(9):1126-9. doi: 10.1016/j.leukres.2014.06.015. Epub 2014 Jul 6.
8
Antiemetic role of thalidomide in a rat model of cisplatin-induced emesis.沙利度胺在顺铂诱导呕吐大鼠模型中的止吐作用
Cell Biochem Biophys. 2014 Sep;70(1):361-5. doi: 10.1007/s12013-014-9921-8.
9
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).免疫调节剂来那度胺和泊马度胺通过调节 E3 泛素连接酶复合物 CRL4(CRBN)，诱导 T 细胞抑制因子 Ikaros 和 Aiolos 的降解，从而共同刺激 T 细胞。
Br J Haematol. 2014 Mar;164(6):811-21. doi: 10.1111/bjh.12708. Epub 2013 Dec 13.
10
Pomalidomide is teratogenic in rats and rabbits and can be neurotoxic in humans.泊马度胺在大鼠和兔子中具有致畸性，对人类可能具有神经毒性。
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):E4819. doi: 10.1073/pnas.1317084110. Epub 2013 Dec 3.
Zotero 插件